Panahi M, Alli Z, Cheng X, Belbaraka L, Belgoudi J, Sardana R, Phipps J, Altosaar I (2004) Recombinant protein expression plasmids optimized for industrial E
doi: 10.1016/0005-2760(88)90020-3 34 DanielliJF
Following the SCALE clinical trial program, it received a second FDA approval in December 2014 as Saxenda for chronic weight management making it the first GLP-1 agonist approved for obesity treatment
Injectable glutathione should not be expected to produce uniform or guaranteed outcomes, and some individuals may experience minimal noticeable benefits despite proper use
Injury and Bone Stress Risk Lower body weight + reduced intake can mean lower bone density over time and increased risk of stress fractures, which may be a concern for high-mileage runners or those with a history of RED-S (Relative Energy Deficiency in Sport)